TNSN01123A1 - Formes posologiques nouvelles a liberation controlee - Google Patents

Formes posologiques nouvelles a liberation controlee

Info

Publication number
TNSN01123A1
TNSN01123A1 TNTNSN01123A TNSN01123A TNSN01123A1 TN SN01123 A1 TNSN01123 A1 TN SN01123A1 TN TNSN01123 A TNTNSN01123 A TN TNSN01123A TN SN01123 A TNSN01123 A TN SN01123A TN SN01123 A1 TNSN01123 A1 TN SN01123A1
Authority
TN
Tunisia
Prior art keywords
controlled release
core
dosage forms
water
new dosage
Prior art date
Application number
TNTNSN01123A
Other languages
English (en)
Inventor
Elizabeth Appel Leah
C Babcock Walter
Arthur Beyerinck Ronald
Brian Chidlaw Mark
John Curatolo William
Thomas Friesen Dwayne
Max Herbig Scott
Govind Thombre Avinash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN01123A1 publication Critical patent/TNSN01123A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE FORME POSOLOGIQUE A LIBERATION CONTROLEE (10). ELLE COMPREND UN NOYAU ENROBE, LE NOYAU (14,16) COMPRENANT UNE COMPOSITION CONTENANT UN MEDICAMENT (14) ET UNE COMPOSITION POUVANT GONFLER DANS L'EAU (16), CHACUNE OCCUPANT UNE REGION DISTINCTE DANS LEDIT NOYAU. L'ENROBAGE (18) AUTOUR DUDIT NOYAU EST PERMEABLE A L'EAU ET INSOLUBLE DANS L'EAU ET COMPORTE AU MOINS UN ORIFICE DE LIBERATION (20). APPLICATION : LIBERATION CONTROLEE D'UN AGENT BENEFIQUE OU D'UN MEDICAMENT DANS UN ENVIRONNEMENT D'UTILISATION.
TNTNSN01123A 2000-08-09 2001-08-08 Formes posologiques nouvelles a liberation controlee TNSN01123A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09

Publications (1)

Publication Number Publication Date
TNSN01123A1 true TNSN01123A1 (fr) 2005-11-10

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01123A TNSN01123A1 (fr) 2000-08-09 2001-08-08 Formes posologiques nouvelles a liberation controlee

Country Status (30)

Country Link
US (2) US20030086972A1 (fr)
EP (1) EP1326587A2 (fr)
JP (1) JP2004505907A (fr)
KR (1) KR20030024844A (fr)
CN (1) CN1461212A (fr)
AP (1) AP2001002237A0 (fr)
AU (1) AU2002229141A1 (fr)
BG (1) BG107538A (fr)
BR (1) BR0113067A (fr)
CA (1) CA2418907A1 (fr)
DO (1) DOP2001000229A (fr)
EA (1) EA200300081A1 (fr)
EC (1) ECSP034455A (fr)
EE (1) EE200300055A (fr)
GT (1) GT200100161A (fr)
HR (1) HRP20030082A2 (fr)
HU (1) HUP0300722A2 (fr)
IL (1) IL154012A0 (fr)
IS (1) IS6686A (fr)
MA (1) MA26939A1 (fr)
MX (1) MXPA03001209A (fr)
NO (1) NO20030627L (fr)
OA (1) OA12365A (fr)
PA (1) PA8524901A1 (fr)
PE (1) PE20020307A1 (fr)
PL (1) PL360658A1 (fr)
SV (1) SV2002000586A (fr)
TN (1) TNSN01123A1 (fr)
UY (1) UY26876A1 (fr)
WO (1) WO2002011702A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (fr) 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
JP4100910B2 (ja) * 1999-12-23 2008-06-11 ファイザー・プロダクツ・インク ヒドロゲル駆動の薬物剤形
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
CA2434169C (fr) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
US20040213848A1 (en) 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
WO2003096968A2 (fr) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Systeme de delivrance orale osmotique controlee de medicament
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
ES2529180T3 (es) * 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
EP2255795A1 (fr) * 2002-09-28 2010-12-01 McNeil-PPC, Inc. Forme pharmaceutique à libération immédiate comprenant une coque dotée d'ouvertures
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
WO2005011634A1 (fr) * 2003-08-04 2005-02-10 Pfizer Products Inc. Formes posologiques d'inhibiteurs de la proteine de transfert d'ester de cholesteryle et d'inhibiteurs de la hmg-coa-reductase
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP1845953A1 (fr) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Formes de dosage assurant la liberation controlee et instantanee d'inhibiteurs de proteines de transfert d'ester de cholesteryle et la liberation instantanee d'inhibiteurs de hmg-coa reductase
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
US20080213381A1 (en) * 2005-03-14 2008-09-04 Pharmaceutical Industries Limited Oral Drug Delivery System
CA2600736A1 (fr) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Systeme d'administration pour de multiples medicaments
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
US20070248630A1 (en) * 2006-04-20 2007-10-25 Friden Phillip M Pharmaceutical formulations for iontophoretic methotrexate delivery
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
JP2011512349A (ja) * 2008-02-15 2011-04-21 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド 経口放出制御錠剤
AU2010316741A1 (en) * 2009-11-09 2012-05-24 Capsugel Belgium Nv Delivery carrier
CA2793525C (fr) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Procede d'amelioration de la dissolution d'un agent anticoagulant
BR112014002397B1 (pt) 2011-08-10 2021-08-03 Daiichi Sankyo Company, Limited Formulação sólida na forma de tablete ou cápsula contendo derivado de diamida
JP6284163B2 (ja) * 2013-01-30 2018-02-28 デウン カンパニー，リミテッド 胃腸管内における傷の保護、止血、または癒着の防止のための医薬組成物
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
JP2021515048A (ja) * 2018-03-07 2021-06-17 シアン チェン アンドリュー 不溶性薬物用の水性製剤
IL307342A (en) * 2021-05-28 2023-11-01 Amgen Inc Formulations of Eframilest
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
WO2023063381A1 (fr) * 2021-10-14 2023-04-20 静岡県公立大学法人 Formulation médicamenteuse en poudre

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
CN1096862C (zh) * 1994-05-06 2002-12-25 辉瑞大药厂 阿齐霉素的控释剂型
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
EA002481B1 (ru) * 1997-07-01 2002-06-27 Пфайзер Продактс Инк. Композиция на основе солюбилизированного сертралина
EP0999830A1 (fr) * 1997-07-01 2000-05-17 Pfizer Inc. Sels de sertraline et formes posologiques de sertraline, a liberation prolongee
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2346335C (fr) * 1998-10-13 2006-04-18 Pfizer Products Inc. Concentre de sertraline par voie orale
EP1027888B1 (fr) * 1999-02-10 2009-06-10 Pfizer Products Inc. Dispositif osmotique pour délivrer des dispersions solides amorphes des médicaments
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
CN1726012A (zh) * 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放

Also Published As

Publication number Publication date
NO20030627D0 (no) 2003-02-07
US20040052845A1 (en) 2004-03-18
MXPA03001209A (es) 2003-06-30
PL360658A1 (en) 2004-09-20
EP1326587A2 (fr) 2003-07-16
ECSP034455A (es) 2003-03-10
UY26876A1 (es) 2002-03-22
MA26939A1 (fr) 2004-12-20
BR0113067A (pt) 2003-07-01
BG107538A (bg) 2003-11-28
US20030086972A1 (en) 2003-05-08
HUP0300722A2 (hu) 2003-11-28
WO2002011702A2 (fr) 2002-02-14
AP2001002237A0 (en) 2001-09-30
GT200100161A (es) 2002-03-22
WO2002011702A3 (fr) 2002-11-28
IL154012A0 (en) 2003-07-31
HRP20030082A2 (en) 2003-04-30
DOP2001000229A (es) 2002-09-30
EE200300055A (et) 2004-12-15
OA12365A (en) 2006-05-16
CA2418907A1 (fr) 2002-02-14
AU2002229141A1 (en) 2002-02-18
PA8524901A1 (es) 2002-04-25
CN1461212A (zh) 2003-12-10
EA200300081A1 (ru) 2003-08-28
PE20020307A1 (es) 2002-04-23
JP2004505907A (ja) 2004-02-26
KR20030024844A (ko) 2003-03-26
SV2002000586A (es) 2002-10-24
NO20030627L (no) 2003-04-08
IS6686A (is) 2003-01-16

Similar Documents

Publication Publication Date Title
TNSN01123A1 (fr) Formes posologiques nouvelles a liberation controlee
TNSN00253A1 (fr) Forme posologique de medicament a liberation controlee
TNSN00251A1 (fr) Forme posologique de sertraline stratifiee commandee par hydrogel
WO2004108067A3 (fr) Systeme de distribution de medicaments programme
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
ES2111547T3 (es) Comprimido de liberacion prolongada.
ID24818A (id) Komposisi farmasi yang digunakan pada selaput lendir
NO20000284D0 (no) Tanninsyre-polymerblandinger for kontrollert frigivelse av farmasoeytiske midler, saerlig i munnhulen
PL353738A1 (en) Composition containing an active substance, production and use thereof
EP1354602A4 (fr) Compositions medicinales contenant un diuretique et un agent renforcant la resistance a l'insuline
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
IT1306179B1 (it) Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale.
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
WO2002036105A3 (fr) Utilisation d'agents sequestrants de cortisol dans le cadre du traitement de troubles lies a l'hypercortisolemie
UY26503A1 (es) " forma de dosificación de fármacos accionada por un hidrogel"
ECSP003856A (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
FR2806302B1 (fr) Composition cosmetique ou pharmaceutique sous forme d'un gel aqueux solide, comprenant un alcool polyvinylique et un alcool polyhydrique
RU97120482A (ru) Композиция ингредиентов для водки "целебная"
IT1304852B1 (it) Miscela di piante medicinali per la prevenzione e la cura delleemorroidi.
AR039314A1 (es) Formulaciones farmaceuticas de liberacion retrasada